MASLD beyond the liver: decoding the gut-genetic-metabolic nexus
This narrative review maps gut-liver axis mechanisms in MASLD but generates no new causal evidence and does not support direct therapeutic recommendations.
| Population | Adults with MASLD/MASH across different histological stages |
|---|---|
| Intervention | Characterization of the gut-genetic-metabolic nexus (microbiota, microbial metabolites, genetic factors, inflammatory pathways) |
| Comparator | Not applicable (narrative review without formal control group) |
| Outcome | Gut dysbiosis and hepatic steatosis; TMAO and insulin resistance; Butyrate and intestinal barrier integrity; IPA/IAA and hepatic steatosis; Apelin as marker of fibrosis and HCC; LPS/TLR4 and hepatic inflammation; Secondary bile acids and fibrosis/hepatocyte injury |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| Gut dysbiosis and hepatic steatosis | Qualitative association; in the pooled effect size or 95% CI reported | — | Low | — | |
| TMAO and insulin resistance | Qualitative association; in the pooled effect size or 95% CI reported | — | Low | — | |
| Butyrate and intestinal barrier integrity | Qualitative protective association; in the pooled effect size or 95% CI reported | — | Low | — | |
| IPA/IAA and hepatic steatosis | Qualitative improvement in steatosis with supplementation; in the effect size or 95% CI reported | — | Low | — | |
| Apelin as marker of fibrosis and HCC | Qualitative correlation with advanced fibrosis and HCC risk; in the effect size or 95% CI reported | — | Low | — | |
| LPS/TLR4 and hepatic inflammation | Qualitative mechanistic association; in the pooled effect size or 95% CI reported | — | Low | — | |
| Secondary bile acids and fibrosis/hepatocyte injury | Qualitative association with steatosis, inflammation and fibrosis; in the pooled effect size or 95% CI reported | — | Low | — |
Context
MASLD affects approximately 30% of the global population and lacks approved therapies for most disease stages. Understanding the role of the microbiota, genetics, and lipid metabolism is necessary to identify therapeutic targets. Narrative reviews such as this synthesize mechanistic hypotheses but do not replace clinical trials.
What the study showed
The review describes consistent associations between intestinal dysbiosis and MASLD: reduction of butyrate-producing bacteria (e.g., Faecalibacterium), increase of endotoxin producers, and alteration of metabolites such as TMAO, secondary bile acids, and IPA/IAA. These findings derive primarily from observational human studies and experimental models (germ-free, FMT in animals), with no quantified effect magnitude reported in the review. No 95% CI or absolute effect sizes are reported for clinical outcomes. The direction of described effects consistently points toward disease progression being worsened by dysfunctional microbiota.
How it was done
Narrative review without registered protocol, without systematized search strategy, and without formal risk-of-bias assessment of included studies. Integrates literature from observational studies, experimental (animal/germ-free), isolated clinical trials, and genetic data. No consolidated sample size or defined follow-up duration.
Effect magnitude
No effect size with 95% CI is reported. The review cites qualitative associations between dysbiosis and MASLD, without meta-analysis or quantitative data pooling.
Risk of bias
Narrative review without PROSPERO registration, without PRISMA, without quality assessment tool (AMSTAR-2 not applied). High risk of literature selection bias and absence of quantitative synthesis. Most cited human studies are observational, limiting causal inference. Animal model data are not directly transferable to humans.
What this study does NOT prove
This review does not prove causality between dysbiosis and MASLD in humans, does not demonstrate efficacy of any microbiota intervention on clinical outcomes, and is not generalizable to pediatric populations or MASLD without obesity.
In clinical practice
No direct clinical practice change is supported by this review. Clinicians should await RCTs testing microbiota interventions (probiotics, FMT, metabolite modulators) with validated histological outcomes. The only FDA-approved drug for non-cirrhotic MASH F2-F3 remains resmetirom.
Limitations
Narrative review without PROSPERO registration, without PRISMA, without quality assessment tool (AMSTAR-2 not applied). High risk of literature selection bias and absence of quantitative synthesis. Most cited human studies are observational, limiting causal inference. Animal model data are not directly transferable to humans.
What is still missing
High-quality RCTs testing microbiota modulation (FMT, specific probiotics, dietary intervention) with primary histological outcomes (MASH resolution, fibrosis regression) are needed. Prospective genetic studies integrating risk variants (PNPLA3, TM6SF2) with microbial composition are absent.
Technical appendix
Version history
- 1.0 · 2026-10-15 — Auto-generated under Evidence Standard v1.0